|
|
|
Çѱ¹È¯°æ»ý¹°ÇÐȸ / v.27, no.1, 2009³â, pp.58-65
|
NaringeninÀÌ NF-$kappa$B, AP-1 ¾ïÁ¦¸¦ ÅëÇÑ MMP-9 Ȱ¼º ¹× ¹ßÇö ¾ïÁ¦ È¿°ú
( Inhibitory Effect of Naringenin on MMP-9 Activity and Expression in HT-1080 Cells ) |
| ä¼öö;°íÀº°æ;¼Àº¼±;À¯±Ùâ;³ª¸í¼®;±èÀμ÷;ÀÌÁ¾ºó; Àü³²´ëÇб³ »ý¹°Çаú;Àü³²´ëÇб³ »ý¹°Çаú;Àü³²´ëÇб³ »ý¹°Çаú;µ¿½Å´ëÇб³ ¾È°æ±¤Çаú;±¤ÁÖ¿©ÀÚ´ëÇб³ ¹Ì¿ë°úÇаú;ÃÊ´ç´ëÇб³ ¾È°æ±¤Çаú;Àü³²´ëÇб³ »ý¹°Çаú;
|
|
|
 |
|
| |
| ÃÊ ·Ï |
| NaringeninÀº flavonoid±¸Á¶ÀÇ °¨±Ö·ù °úÇÇ¿¡ ´Ù·® ÇÔÀ¯µÇ¾î ÀÖÀ¸¸ç Ç×¾Ï ¹× Ç×»êÈ µîÀÇ ´Ù¾çÇÑ »ý¸®È°¼ºÀ» °¡Áö´Â °ÍÀ¸·Î º¸°íµÇ¾ú´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼´Â HT-1080 ¼¶À¯À°Á¾¼¼Æ÷ÀÇ ÀüÀÌ¿¡ ´ëÇÑ ¿µÇâÀ» Á¶»çÇÏ¿´´Ù. ¸ÕÀú NaringeninÀÌ ¾Ï¼¼Æ÷ÀÇ À̵¿¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¾Ë¾Æº¸±â À§ÇØ migrationassay¸¦ ÇÑ °á°ú, NaringeninÀÌ ¾Ï¼¼Æ÷ÀÇ À̵¿À» ³óµµ ÀÇÁ¸ÀûÀ¸·Î ¾ïÁ¦½ÃÄ×´Ù. ¾ÏÀÇ ÀüÀÌ¿¡ ÀÖ¾î¼ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ´Ü¹éÁúºÐÇØÈ¿¼ÒÀÎ matrix metalloproteinase-9 (MMP-9)ÀÇ È°¼ºµµ¸¦ ÃøÁ¤Çϱâ À§ÇØ gelatin zymography¸¦ ÇÑ °á°ú, NaringeninÀÌ PMA¿¡ ÀÇÇØ Áõ°¡µÈ MMP-9ÀÇ È¿¼Ò Ȱ¼ºµµ¸¦ ³óµµ ÀÇÁ¸ÀûÀ¸·Î °¨¼Ò½ÃÄ×´Ù. ¶ÇÇÑ MMP-9¿Í TIMP-1ÀÇ À¯ÀüÀÚ ¹ßÇö¿¡ ´ëÇÑ NaringeninÀÇ ¿µÇâÀ» RT-PCR¹æ¹ýÀ¸·Î Á¶»çÇÑ °á°ú, NaringeninÀÌ PMA¿¡ ÀÇÇØ Áõ°¡µÈ MMP-9ÀÇ mRNA¹ßÇöÀ» ³óµµ ÀÇÁ¸ÀûÀ¸·Î °¨¼Ò½ÃÄ×À¸³ª TIMP-1ÀÇ mRNA¹ßÇö¿¡´Â º¯È°¡ ¾ø¾ú´Ù. MMP-9¹ßÇö °¨¼Ò¿¡ °ü¿©ÇÏ´Â Àü»çÁ¶ÀýÀÎÀÚ¸¦ È®ÀÎÇϱâ À§ÇØ promoterassay¸¦ ÇÑ °á°ú, NaringeninÀÌ PMA¿¡ ÀÇÇØ Áõ°¡µÈ MMP-9 ¹× NF-$kappa$B, AP-1ÀÇ PromoterȰ¼ºÀ» ³óµµ ÀÇÁ¸ÀûÀ¸·Î °¨¼Ò½Ã Ä×´Ù. ¶ÇÇÑ MMP-9ÀÇ ÀüÀÚÁ¶ÀýÀÎÀÚÀÎ NF-$kappa$B¿Í AP-1ÀÇ °áÇÕ È°¼ºµµ¸¦ electrophoretic mobility shift assay·Î È®ÀÎÇÑ °á°ú NaringeninÀÌ PMA¿¡ ÀÇÇØ Áõ°¡µÈ NF-$kappa$B¿Í AP-1ÀÇ °áÇÕ È°¼ºµµ¸¦ ³óµµ ÀÇÁ¸ÀûÀ¸·Î °¨¼Ò½ÃÄ×´Ù. °á·ÐÀûÀ¸·Î NaringeninÀÌ Àü»çÁ¶ÀýÀÎÀÚÀÎ NF-$kappa$B¿Í AP-1ÀÇ È°¼ºÀ» ¾ïÁ¦ÇÔÀ¸·Î½á MMP-9ÀÇ À¯ÀüÀÚ ¹ßÇö ¹× È¿¼Ò Ȱ¼ºÀ» ¾ïÁ¦ÇÏ°í ±× °á°ú ¾Ï¼¼Æ÷ÀÇ À̵¿°ú ħÀ±À» ¾ïÁ¦ÇÏ´Â °ÍÀ» ¾Ë ¼ö ÀÖ´Ù. |
|
| The chemopreventive effects of naringenin derived from citrus on tumor migration and the possible mechanisms involved in this protection were investigated in HT-1080 tumor cells. In this study, we found that naringenin reduced phorbol 12-myristate 13-acetate (PMA)-enhanced matrix metalloproteinases (MMP)-9 activation in a dose-dependant manner and further inhibited HT-1080 cell migration. In addition, naringenin suppressed PMA-enhanced expression of MMP-9 protein, mRNA and transcription activity levels through suppression of nuclear factor $kappa$B (NF-$kappa$B) activation and activator protein-1 (AP-1) translocation without changing tissue inhibitor of metalloproteinase (TIMP)-1 level. Therefore, our results suggested that the inhibitory effects of naringenin on MMP-9 activation, relation of tumor migration in vitro possibly involve mechanisms related to its ability to suppress PMA-enhanced MMP-9 gene and protein expression through NF-$kappa$B activation and AP-1 translocation. Overall, naringenin may be a valuable anti-invasive drug candidate for cancer therapy. |
| |
| Ű¿öµå |
| AP-1;MMP-9;Naringenin;NF-$kappa$B;TIMP-1; |
| |
|
|
 |
|
ȯ°æ»ý¹° / v.27, no.1, 2009³â, pp.58-65
Çѱ¹È¯°æ»ý¹°ÇÐȸ
ISSN : 1226-9999
UCI : G100:I100-KOI(KISTI1.1003/JNL.JAKO200920258463366)
¾ð¾î : Çѱ¹¾î |
|
| ³í¹® Á¦°ø : KISTI Çѱ¹°úÇбâ¼úÁ¤º¸¿¬±¸¿ø |
|
|
|
|
|
|